okt 17, 2018: middag - 1:25 p.m.
Ed Hurwitz is an accomplished biotech executive and investor. Prior to joining MPM, he was founder and Managing Director of Precision BioVentures where he focused on founding and seeding start-up biotechnology companies, including Viewpoint Therapeutics. Prior to that, he was a Director at Alta Partners where he led 12 successful investments including Applied Genetic Technologies Corporation, Avid Radiopharmaceuticals (acquired by Lilly), Calistoga Pharmaceuticals (acquired by Gilead), Cara Therapeutics, FoldRx Pharmaceuticals (acquired by Pfizer), MacroGenics and Taligen Therapeutics (acquired by Alexion).
Over the course of his career, he has been a Senior Vice President and CFO of Affymetrix, a pioneer microarray supplier, and a biotech research analyst for both Robertson Stephens & Company and Smith Barney Shearson. Prior to that he practiced law at Cooley Godward LLP.
Ed earned his J.D. and M.B.A. degrees from the University of California, Berkeley%u2019s Boalt School of Law and Haas School of Business, and his B.A. in Molecular Biology from Cornell University.
Moderator: Susanne Mulligan, Managing Director, BMO Capital Markets